Article Sidebar
Views pdf: 81
EFFECTIVENESS OF LIPOSOMAL DOXORUBICIN IN THE TREATMENT OF RECURRENT OR METASTASIS ENDOMETRIAL CANCER AT K HOSPITAL
Main Article Content
Abstract
Objectives: This study aims to evaluate overall response rate and progression free survival of pegylated liposomal doxorubicin (PLD) in patients with recurrent/ metastasis endometrial cancer. Materials and methods: This non – interventional observational study used medical record of patients diagnosed with recurrent/ metastasis endometrial cancer who received PLD at National Cancer Hospital from June 2017 to June 2023. Baseline characteristics, PLD dose, treatment reponse and progression free survival were extracted. Results: A total of 56 patients with recurrent/ metastasis endometrial cancer were included in this study. 11 of 56 (19.7%) patients had an objective response, of which 3 (5.4%) were complete response and 8 (14.3%) achieved partial response. Stable disease was seen in 29 patients (51.8%), and 16 patients (28.5%) had disease progression. Median progression free survival was 18.3 weeks. Conclusions: Liposomal doxorubicin monotherapy is effective in recurrent/ metastasis endometrial cancer patients.
Article Details
Keywords
Recurrent/ metastasis endometrial cancer; liposomal doxorubicin.
References
2. https://gco.iarc.fr/today/fact-sheets-populations
3. Escobar PF, et al. Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer. J Cancer Res Clin Oncol. 2003 Nov;129(11):651-4. doi: 10.1007/s00432-003-0497-8. Epub 2003 Sep 23. PMID: 14505047.
4. Heffernan K, et al. Previously treated recurrent or advanced endometrial cancer in England: A real-world observational analysis. Gynecol Oncol. 2022 Aug;166(2):317-325. doi: 10.1016/ j.ygyno. 2022.06.011. Epub 2022 Jun 22. PMID: 35752507.
5. Homesley HD, et al. Phase II trial of liposomal doxorubicin at 40 mg/m(2) every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2005 Aug;98(2):294-8. doi: 10.1016/j.ygyno.2005.05.016. PMID: 15975638.
6. Muggia FM, et al. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2002 May 1;20(9):2360-4. doi: 10.1200/JCO.2002.08.171. PMID: 11981008.
7. Julius JM, et al. Evaluation of pegylated liposomal doxorubicin dose on the adverse drug event profile and outcomes in treatment of recurrent endometrial cancer. Int J Gynecol Cancer. 2013 Feb;23(2):348-54. doi: 10.1097/ IGC.0b013e31827c18f3. PMID: 23295941.
8. Siegenthaler F, et al. Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification. Gynecol Oncol. 2022 May;165(2):230-238. doi: 10.1016/ j.ygyno. 2022.02.024. Epub 2022 Mar 8. PMID: 35277281.